Fabrissio Portelinha Graffunder

Fabrissio Portelinha Graffunder

Auto-generated profile, based on publicly available information

Fabrissio Portelinha Graffunder

Governador Celso Ramos Hosp, Div Ophthalmol, Florianopolis, SC, Brazil

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2024 in Clinical Ophthalmology
Verified
Journal Article
Open access
LJLeonardo Justino
Leonardo Justino
GJGustavo Justino
Gustavo Justino
FGFabrissio Graffunder
Fabrissio Graffunder
WBWilliam Binotti
William Binotti
AKAli Khodor
Ali Khodor
JCJonathan Caranfa
Jonathan Caranfa
Purpose: To assess efficacy and safety of brolucizumab versus aflibercept in patients with diabetic macular edema (DME). Patients and Methods: We performed a systematic review and meta-analysis with trial sequential analysis (TSA). We searched Embase, Cochrane Central Register of Controlled Trials and PubMed databases from inception to February 16, 2024 for randomized controlled trials (RCTs) comparing brolucizumab with aflibercept in patients with DME and reporting any of the visual, anatomical and safety outcomes of interest. We conducted a TSA of safety outcomes to assess the risk of statistical errors. Results: 1253 patients (1253 eyes) from 3 RCTs were included, of whom 57% received brolucizumab and 43% received aflibercept. Mean follow-up ranged from 52 to 100 weeks. Brolucizumab was non-inferior to aflibercept when comparing the mean change of best-corrected visual acuity from baseline (least squares mean difference [LSMD] 0.29; 95% confidence interval [CI] -1.37 to 1.95; p = 0.73). Change in central subfield thickness was significantly greater in the brolucizumab group compared with aflibercept (LSMD -24.5 mu m; 95% CI -48.2 to -0.7 mu m; p < 0.05). Incidence of adverse events of special interest (AESIs) (risk ratio [RR] 1.7; p = 0.08) and incidence of >= 1 ocular adverse events (AEs) (RR 0.95; p = 0.45) were not significantly different between groups. Conclusion: Brolucizumab was non-inferior in functional outcomes and was superior to aflibercept in anatomical parameters. Ocular AEs and AESIs were numerically low and not statistically significant. Our findings underscore the importance of new RCTs powered to assess safety outcomes in order to suggest brolucizumab as an alternative to the treatment of DME.

1 September 2020 in Arquivos de Gastroenterologia
Verified
Journal Article
Open access
JAJosé Roberto Alves
José Roberto Alves
FGFabrissio Portelinha Graffunder
Fabrissio Portelinha Graffunder
JRJoão Vitor Ternes Rech
João Vitor Ternes Rech
CTCaique Martins Pereira Ternes
Caique Martins Pereira Ternes
IKIago Koerich-Silva
Iago Koerich-Silva
BACKGROUND: Barrett’s esophagus (BE) is a premalignant condition that raises controversy among general practitioners and specialists, especially regarding its diagnosis, treatment, and follow-up protocols. OBJECTIVE: This systematic review aims to present the particularities and to clarify controversies related to the diagnosis, treatment and surveillance of BE. METHODS: A systematic review was conducted on PubMed, Cochrane, and SciELO based on articles published in the last 10 years. PRISMA guidelines were followed and the search was made using MeSH and non-MeSH terms “Barrett” and “diagnosis or treatment or therapy or surveillance”. We searched for complete randomized controlled clinical trials or Phase IV studies, carried out with individuals over 18 years old. RESULTS: A total of 42 randomized controlled trials were selected after applying all inclusion and exclusion criteria. A growing trend of alternative and safer techniques to traditional upper gastrointestinal endoscopy were identified, which could improve the detection of BE and patient acceptance. The use of chromoendoscopy-guided biopsy protocols significantly reduced the number of biopsies required to maintain similar BE detection rates. Furthermore, the value of BE chemoprophylaxis with esomeprazole and acetylsalicylic acid was relevant, as well as the establishment of protocols for the follow-up and endoscopic surveillance of patients with BE based predominantly on the presence and degree of dysplasia, as well as on the length of the follow-up affected by BE. CONCLUSION: Although further studies regarding the diagnosis, treatment and follow-up of BE are warranted, in light of the best evidence presented in the last decade, there is a trend towards electronic chromoendoscopy-guided biopsies for the diagnosis of BE, while treatment should encompass endoscopic techniques such as radiofrequency ablation. Risks of ablative endoscopic methods should be weighted against those of resective surgery. It is also important to consider lifetime endoscopic follow-up for both short and long term BE patients, with consideration to limitations imposed by a range of comorbidities. Unfortunately, there are no randomized controlled trials that have evaluated which is the best recommendation for BE follow-up and endoscopic surveillance (>1 cm) protocols, however, based on current International Guidelines, it is recommended esophagogastroduodenoscopy (EGD) every 5 years in BE without dysplasia with 1 up to 3 cm of extension; every 3 years in BE without dysplasia with >3 up to 10 cm of extension, every 6 to 12 months in BE with low grade dysplasia and, finally, EGD every 3 months after ablative endoscopic therapy in cases of BE with high grade dysplasia.

1 May 2021 in JACC
Verified
Journal Article
Closed access
RCRhanderson Cardoso
Rhanderson Cardoso
FGFabrissio P. Graffunder
Fabrissio P. Graffunder
CTCaique M.P. Ternes
Caique M.P. Ternes
GFGilson Fernandes
Gilson Fernandes
ARAna Vitoria Rocha
Ana Vitoria Rocha
DBDeepak L Bhatt
Deepak L Bhatt